ClinicalTrials.gg
Not yet recruitingNCT07944157Updated Nov 18, 2026

Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling

An interventional study of Yuping Yifei herbal formula and standardized Western medical treatment in COPD (Chronic Obstructive Pulmonary Disease) and Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by First Affiliated Hospital of Ningbo University. Not yet recruiting at 4 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by First Affiliated Hospital of Ningbo University · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
91st of 289
360 · median 160
Started
2026
with 36 others
No phase
121 of 407
32 open now
Primary completion
2030-04
later than 125 of 127 live
Registered
406th of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 91st largest by planned enrollment of the 289 interventional ones that give a count, is one of 37 that started in 2026, is one of 121 with no phase, reaches primary completion later than 125 of the 127 other live ones, and was the 406th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Keywords

  • Core Targets of Airway Inflammation and Remodeling
  • Traditional Chinese Medicine
  • Syndrome Differentiation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Stable cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator /FVC \<0.70.
  2. Age 40 years or older, any sex.
  3. Clinically stable during the 4 weeks before enrollment, without a COPD exacerbation or initiation/change of systemic antibiotics or systemic for worsening respiratory symptoms.
  4. Predominant TCM syndrome of lung qi deficiency, lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney qi-yin deficiency, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  5. Able to understand the study and provide written .
  6. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Stable COPD cohort:

  1. Systemic antibiotics or systemic glucocorticoids within 2 weeks before enrollment, or long-term systemic glucocorticoid maintenance therapy.
  2. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  3. Active pulmonary tuberculosis, pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  4. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  5. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  6. Allergy to study herbal components or a to herbal therapy.
  7. Pregnancy, breastfeeding, or planned pregnancy.
  8. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  9. Investigator judges participation unsuitable.

Inclusion Criteria - Hospitalized AECOPD cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC \<0.70; current acute exacerbation assessed clinically.
  2. Age 40 years or older, any sex.
  3. Hospitalized for the current AECOPD episode, with screening and randomization completed within 24 hours after admission.
  4. Onset of acute worsening of respiratory symptoms no more than 5 days before enrollment.
  5. Cumulative systemic antibiotic and/or systemic glucocorticoid treatment for the current episode no more than 48 hours before enrollment.
  6. Predominant TCM syndrome of phlegm-heat obstructing the lung or phlegm-turbidity obstructing the lung, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  7. Able to understand the study and provide written informed consent.
  8. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Hospitalized AECOPD cohort:

  1. Deterioration not attributable to AECOPD; active pulmonary tuberculosis, invasive fungal disease, or pulmonary infection requiring pathogen-specific treatment as judged by the investigator.
  2. Pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  3. Systemic antibiotics or systemic glucocorticoids for reasons other than the current exacerbation within 2 weeks, or long-term systemic glucocorticoid maintenance therapy.
  4. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  5. Immediate need for intensive care, invasive mechanical ventilation, altered consciousness, or hemodynamic instability at enrollment.
  6. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  7. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  8. Allergy to study herbal components or a contraindication to herbal therapy.
  9. Pregnancy, breastfeeding, or planned pregnancy.
  10. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  11. Investigator judges participation unsuitable.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Stable COPD - Lung Qi Deficiency - Optimized Yuping Yifei Formula

    24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: Yuping Yifei herbal formula · Drug: standardized Western medical treatment

  • Active comparator
    Stable COPD - Lung Qi Deficiency - Standard Western Treatment

    24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

  • Experimental
    Stable COPD - Lung-Spleen Qi Deficiency - Optimized Liujun Fuzheng Formula

    24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: standardized Western medical treatment · Drug: Liujun Fuzheng herbal formula

  • Experimental
    Stable COPD - Lung-Spleen Qi Deficiency - Innovative Qiyi Peitu Formula

    24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: standardized Western medical treatment · Drug: Qiyi Peitu herbal formula

  • Active comparator
    Stable COPD - Lung-Spleen Qi Deficiency - Standard Western Treatment

    24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

  • Experimental
    Stable COPD - Lung-Kidney Qi Deficiency - Optimized Shenqi Naqi Formula

    24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: standardized Western medical treatment · Drug: Shenqi Naqi herbal formula

  • Experimental
    Stable COPD - Lung-Kidney Qi Deficiency - Innovative Fufei Gushen Formula

    24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: standardized Western medical treatment · Drug: Fufei Gushen herbal formula

  • Active comparator
    Stable COPD - Lung-Kidney Qi Deficiency - Standard Western Treatment

    24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

  • Experimental
    Stable COPD - Lung-Kidney Qi-Yin Deficiency - Optimized Shengmai Runyuan Formula

    24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks.

    Drug: standardized Western medical treatment · Drug: Shengmai Runyuan herbal formula

  • Active comparator
    Stable COPD - Lung-Kidney Qi-Yin Deficiency - Standard Western Treatment

    24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

  • Experimental
    AECOPD - Phlegm-Heat Obstructing Lung - Optimized Qinbei Qingfei Formula

    24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks.

    Drug: standardized Western medical treatment · Drug: Qinbei Qingfei herbal formula

  • Active comparator
    AECOPD - Phlegm-Heat Obstructing Lung - Standard Western Treatment

    24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

  • Experimental
    AECOPD - Phlegm-Turbidity Obstructing Lung - Optimized Erchen Shunqi Formula

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks.

    Drug: standardized Western medical treatment · Drug: Erchen Shunqi herbal formula

  • Experimental
    AECOPD - Phlegm-Turbidity Obstructing Lung - Innovative Banlou Kuanxiong Formula

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks.

    Drug: standardized Western medical treatment · Drug: Banlou Kuanxiong herbal formula

  • Active comparator
    AECOPD - Phlegm-Turbidity Obstructing Lung - Standard Western Treatment

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula.

    Drug: standardized Western medical treatment

Interventions

  • DrugYuping Yifei herbal formula

    Stable COPD, lung qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fangfeng 6 g, Wuweizi 6 g, Ziwan 9 g, and Sangbaipi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • Drugstandardized Western medical treatment

    Administer standardized Western medical treatment in accordance with the GOLD guidelines

  • DrugLiujun Fuzheng herbal formula

    Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 12 g, Chenpi 9 g, ginger-processed Banxia 9 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • DrugQiyi Peitu herbal formula

    Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 15 g, Shanyao 20 g, Yiyiren 20 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • DrugShenqi Naqi herbal formula

    Stable COPD, lung-kidney qi deficiency: Dangshen 20 g, Huangqi 30 g, salt-processed Duzhong 12 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Fuling 12 g, and ginger-processed Banxia 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • DrugFufei Gushen herbal formula

    Stable COPD, lung-kidney qi deficiency: Huangqi 30 g, Renshen 6 g, Yinyanghuo 9 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Gouqizi 15 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • DrugShengmai Runyuan herbal formula

    Stable COPD, lung-kidney qi-yin deficiency: Dangshen 15 g, Zhemaidong 10 g, Wuweizi 6 g, Shudihuang 15 g, Shanzhuyu 12 g, Shanyao 20 g, Huangqi 30 g, and Danshen 15 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

  • DrugQinbei Qingfei herbal formula

    Hospitalized AECOPD, phlegm-heat obstructing the lung: Huangqin 9 g, Zhebeimu 10 g, Sangbaipi 12 g, Yuxingcao 20 g, Qingbanxia 9 g, Zisuzi 9 g, and honey-processed Mahuang 5 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

  • DrugErchen Shunqi herbal formula

    Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Zisuzi 9 g, Baijiezi 6 g, and Laifuzi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

  • DrugBanlou Kuanxiong herbal formula

    Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Gualoupi 9 g, Gualouren 6 g, Kuxingren 9 g, and Jiegeng 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

06

What researchers measure

Primary outcomes

  1. Change in FEV1 Percent Predicted at Week 24 (Stable COPD)

    Absolute change from baseline in post-bronchodilator forced expiratory volume in one second as a percentage of the predicted value (FEV1%pred).

    Time frame: Baseline (T0) and Week 24

  2. Time to First Hospitalized COPD Exacerbation Through Week 24 (Stable COPD)

    Time from T0 to the first acute COPD exacerbation requiring hospitalization. Exacerbations managed without hospitalization are not counted for this outcome.

    Time frame: From baseline (T0) through Week 24

  3. Number of Hospitalized COPD Exacerbations Through Week 24 (Stable COPD)

    Count of acute COPD exacerbations requiring hospitalization from T0 through Week 24. Episodes treated only in outpatient or emergency settings without admission are not counted.

    Time frame: From baseline (T0) through Week 24

  4. Change in Dyspnea Numeric Rating Scale Score on Day 4 (AECOPD)

    Absolute change from baseline in the average dyspnea numeric rating scale (NRS) score over the preceding 24 hours.

    Time frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

  5. Proportion With at Least a 1-Point Improvement in Dyspnea NRS on Day 4 (AECOPD)

    Proportion of participants whose average dyspnea NRS score over the preceding 24 hours decreases by at least 1 point from baseline.

    Time frame: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

  6. Total Length of Hospital Stay for the Index AECOPD Admission

    Number of days from admission for the index acute exacerbation to hospital discharge.

    Time frame: From hospital admission to discharge for the index AECOPD episode

Secondary outcomes

  1. Change in COPD Assessment Test (CAT) Score

    Change from baseline in CAT total score in the stable COPD and AECOPD cohorts.

    Time frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

  2. Change in TCM Syndrome Efficacy Score

    Change from baseline in the syndrome-specific TCM symptom score using the appropriate stable-phase or AECOPD assessment scale.

    Time frame: Baseline and scheduled assessments through Week 24

  3. Change in St. George's Respiratory Questionnaire (SGRQ) Score

    Change from baseline in SGRQ total score.

    Time frame: Baseline, Week 12, and Week 24

  4. Change in Modified Medical Research Council (mMRC) Dyspnea Grade

    Change from baseline in the mMRC dyspnea grade, an ordinal measure of breathlessness, in stable COPD and hospitalized AECOPD participants.

    Time frame: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

  5. Change in Airway Wall Area Percentage on HRCT

    Absolute change from baseline in airway wall area percentage (WA%) derived from quantitative high-resolution computed tomography.

    Time frame: Baseline and Week 24

  6. Change in Emphysema Index on HRCT

    Absolute change from baseline in emphysema index derived from quantitative high-resolution computed tomography.

    Time frame: Baseline and Week 24

  7. Change in Airway Wall Thickness on HRCT

    Absolute change from baseline in airway wall thickness derived from quantitative high-resolution computed tomography.

    Time frame: Baseline and Week 24

  8. Change in C-Reactive Protein Concentration

    Absolute change from baseline in peripheral-blood C-reactive protein concentration as an inflammation marker.

    Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

  9. Change in Interleukin-6 Concentration

    Absolute change from baseline in interleukin-6 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

    Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

  10. Change in Interleukin-8 Concentration

    Absolute change from baseline in interleukin-8 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

    Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

  11. Change in Tumor Necrosis Factor Alpha Concentration

    Absolute change from baseline in tumor necrosis factor alpha concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

    Time frame: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

  12. Change in FEV1 Percent Predicted After AECOPD

    Absolute change from baseline in post-bronchodilator FEV1 percent predicted among hospitalized AECOPD participants able to undergo safe and valid spirometry.

    Time frame: Baseline when feasible, Weeks 12 and 24

  13. Incidence of Adverse Events

    Number and proportion of participants experiencing at least one adverse event during treatment and follow-up, with event type, severity, and relationship to study herbal treatment recorded.

    Time frame: From baseline through Week 24

  14. Incidence of Serious Adverse Events

    Number and proportion of participants experiencing at least one serious adverse event during treatment and follow-up, with severity, management, outcome, and relationship to study herbal treatment recorded.

    Time frame: From baseline through Week 24

07

Study locations

4 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the main publication, including baseline characteristics, treatment allocation, and outcome data, will be available upon reasonable request. Direct personal identifiers will not be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning after publication of the main study results, subject to applicable institutional and ethics requirements.

Access criteria: Qualified researchers may request access by submitting a research proposal to the study contact, together with ethics approval where applicable. Requests will be reviewed by the study team and relevant institutional or ethics bodies. Approved researchers will receive de-identified data under a data-use agreement. Re-identification and onward sharing are prohibited.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2030, 39 months later.

Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 39 months is above that.

Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
May 1, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944157
Lead sponsor
First Affiliated Hospital of Ningbo University
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Apr 1, 2030 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

chao cao
Contact
caocdoctor@163.com
+8618258796166

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion